Clinical Trial Update: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 open-label study evaluating AK127 in combination with AK104 for safety, tolerability, and preliminary efficacy in patients with advanced malignant tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK127

Snippet

Sponsor: Akeso | Conditions: Advanced Malignant Tumors | Phase 1 | Status: RECRUITING